您的位置: 首页 > 农业专利 > 详情页

Factor XII inhibitors for the treatment of silent cerebral ischemia or stroke
专利权人:
The General Hospital Corporation;CSL Behring GmbH
发明人:
NAHRENDORF, Matthias,WEISSLEDER, Ralph,DICKNEITE, Gerhard,STOLL, Guido,NOLTE, Marc
申请号:
ES12707624
公开号:
ES2607063T3
申请日:
2012.03.09
申请国别(地区):
ES
年份:
2017
代理人:
摘要:
A Factor XII (FXII) inhibitor for use in the prevention and / or treatment of ischemia in a patient receiving a medical procedure, wherein the medical procedure comprises contact with at least one between: (a) heart, (b ) at least one blood vessel selected from: the aorta, the aortic arch, a carotid artery, a coronary artery, brachiocephalic artery, vertebrobasilar circulation, intracranial arteries, renal artery, a hepatic artery, a mesenteric artery and / or a blood vessel cranial arterial system towards the heart, (c) a venous blood vessel if the patient has a known septal defect; and wherein the medical procedure comprises the release of at least one microembol in at least one of said blood vessels in the body which could lead to said ischemia in at least one target organ and where the FXII inhibitor is administered before , during and / or after the medical procedure, where the target organ is the brain and where the patient has, has had or is at risk of (i) silent cerebral ischemia or (ii) a stroke caused by a non-thrombolizable substance and wherein the FXII inhibitor comprises (i) the wild-type Infestin-4 polypeptide sequence (SEQ ID NO: 1), or a variant thereof, wherein a variant comprises (a) the N-terminal amino acids 2 -13 of the wild-type Infestin-4 sequence and at least one and up to five amino acid mutations outside of said N-terminal amino acids that give rise to differences with the wild-type Infestin-4 sequence; and / or (b) six cysteine residues conserved from the wild-type Infestin-4 sequence and at least 70% homology with the wild-type Infestin-4 sequence; (ii) an anti-FXII antibody, wherein the antibody binds to FXII and inhibits its activity and / or activation.Un inhibidor de Factor XII (FXII) para uso en la prevención y/o el tratamiento de isquemia en un paciente que recibe un procedimiento médico, en donde el procedimiento médico comprende el contacto con al menos uno entre: (a) corazón, (b) al menos un vaso sanguíneo seleccionado entre: la
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充